Weekly update Companies AI-cruiter Recruiting

Strand Therapeutics

Founded: 2018

Location: Boston, MA

Employee range: 1 - 10

Clinical stage: RD

Therapy area: Solid tumors

Drug types: ONC

Lead product: Undisclosed

Product link: https://www.strandtx.com/#about

Funding: $45M A Nov 2022; $52M A Jun 2021; $6M seed Jun 2019

Investors: FPV, Eli Lilly and Company, Potentum Partners, Playground Global

strandtx.com

linkedin.com

job board

Short description:

Gene Therapy

Drug notes:

Undisclosed RD hematological cancers

Long description:

Strand Therapeutics is developing mRNA therapeutics to treat cancer, heart diseases and rare diseases. mRNA has recently emerged as an effective, multi-functional and potentially curative treatment option for many patients. Strand’s approach to mRNA therapeutics is unique - creating mRNA constructs that contain information for self-replication and genetically programmed logic circuits. This application of synthetic biology to RNA therapeutics enables the creation of programmable, long-acting mRNA drugs such that the location, timing and intensity of expression can all be controlled. Stand has initially focused on treatment options for solid tumor cancers.